Windlas Biotech Ltd Q1 FY27 Earnings Call Summary

Event Participants

Executives

3 Ankit Jain, Hitesh Windlas, Komal Gupta

Analysts

7 Ankur Kumar, Avnish Burman, Avnish Tiwari, Dhwanil Desai, Ishit Desai, Kumar Saurabh, Resham Jain, Sajal Kapoor

Financials & KPIs

Geographic & Segment Commentary

• CDMO (Generic Compilations): Delivered ₹207 crores, 29% YoY — the highest growth in a long period. Growth driven by customer expansion, deeper engagement, new product launches, and injectables now contributing to overall revenue. Management cautioned against reading too much into quarterly vertical-level growth, emphasizing company-level consistency.

• Trade Generic & Institutional: Reported ₹30 crores following codeine-based product discontinuation. Ex-codeine business momentum has taken a hit, acknowledged as temporary for a few quarters. Management highlighted geographic expansion, portfolio expansion (150-200 SKUs base, aiming larger), and institutional account additions as recovery levers.

• Exports: Recorded ₹11 crores, 79% YoY. Higher gestation conversion business requiring patient investment; ongoing registration work, new geographies, plant audits. Management remains positive on long-term opportunity but noted quarterly volatility is expected.

Company-Specific & Strategic Commentary

• Plant 6 Commercialization: Mechanical completion done; validations and customer audits ongoing. Targeting end of H1 FY27 (Q2 +15 days) to be fully online. Expansion to core oral solid dosage form (vs. injectables as periphery expansion), so expects faster ramp similar to Plant 2 extension rather than new product development cycle.

• Injectables & Plant 2 Extension: Continue to drive scalable growth. Infrastructure for 2 lines already in place; future capacity addition in injectables would take 6-8 months (machinery, qualification, commissioning) given support facilities are ready.

• Capacity Philosophy: Management deliberately avoids mega-facilities — incremental capacity expansion maintains pricing power with CDMO customers and avoids desperation to fill large blocks. Brownfield oral solid expansion takes ~1 year to bring online.

• Capital Returns: Completed ₹47 crores buyback (promoters excluded) and declared ₹6.30/share dividend for FY26, consistent with shareholder value focus.

• ESOP Expense Impact: Non-cash ESOP expense of ₹7.2 crores in Q1; management highlights ex-ESOP profitability for operational performance.

Guidance & Outlook

Risks & Constraints

Q&A Highlights

CDMO Growth Sustainability

• Question: With CDMO delivering 29% growth, is this driven by injectables now contributing and becoming more sustainable? (Dhwanil Desai)
• Answer: Management cautioned against vertical-level quarterly interpretation. Injectables have been participating in overall revenue but not specific to this quarter. No long-term factors changed; growth comes from consistent execution across customer expansion, deeper engagement, and new launches. (Ankit Jain)

Trade Generics Stagnation & Codeine Bridge

• Question: Even excluding codeine, trade generics have been stagnant at ₹30-35 crores run-rate for 3-4 quarters. How should we read this, and will growth return once codeine is out of the base? (Dhwanil Desai)
• Answer: No guidance provided. Growth is a function of sustained go-to-market strategy, product offerings in trade generics, geographic expansion (new states and deepening existing), and execution hygiene. Management emphasized "fundamentals of the business do not change" and the portfolio approach with 150-200 SKUs being expanded. (Hitesh Windlas)

Plant 6 Operational Milestones

• Question: What specific operating milestones should shareholders track over the next 4-6 quarters to judge if incremental capacity converts into utilization and cash generation rather than just higher revenue? (Sajal Kapoor)
• Answer: Plant 6 is an expansion of core (unlike injectables periphery entry), so ramp should follow Plant 2 extension pattern — existing portfolios offered from Plant 6, plant-level customer approvals, then new customer acquisition leveraging available capacity. Success signals will appear in revenue and cash flow generation. (Hitesh Windlas)

IPM Volume Growth Correlation

• Question: Is Windlas's growth correlated with IPM data? What is sustainable IPM volume growth? (Kumar Saurabh)
• Answer: IPM volume growth was 3.4% in Q1 FY27, a welcome sign after mild/negative volume growth in prior years. As a CDMO, Windlas focuses on volume (not price). Management can't predict sustainability but leverages growth when customers benefit from deeper penetration and bigger brands. (Hitesh Windlas)

Peak Utilization & Export Growth

• Question: At ~65% utilization with Plant 6 coming and no new capex, what is peak utilization? Will export growth continue? (Unidentified Analyst)
• Answer: Peak utilization for this business type is 60-65%, stretchable to 70%. With Plant 6, ₹1,100 crores revenue is achievable, plus 10-15% more via efficiency initiatives and ₹12-15 crores annual maintenance capex. Exports remain positive on long-term opportunity; results are difficult to predict quarterly due to gestation. (Ankit Jain)

Ex-Codeine Trade Generic Growth & Employee Costs

• Question: Has the ex-codeine trade generics business grown YoY this quarter? What drove 17% employee cost growth? (Avnish Burman)
• Answer: Quarterly YoY growth is difficult to determine due to lumpy institutional revenue; codeine removal did impact momentum — acknowledged as temporary. Employee cost drivers: increments, contractual manpower with production growth, and retrospective Uttarakhand minimum wage increase. Nothing extraordinary; EBITDA maintained. (Ankit Jain)

Depreciation & Working Capital

• Question: What is the quarterly depreciation increase from Plant 6? Was there working capital pressure this quarter? (Avnish Burman)
• Answer: Additional depreciation ~₹3 crores per quarter initially (±10-15%), declining over time; starts partially Q2, full from Q3. Working capital increased during quarter due to geopolitical-driven inventory build-up, but by quarter-end it was brought back to prior levels. (Ankit Jain)

Codeine Replacement Strategy & Injectable Capacity

• Question: Is there a like-for-like cough syrup replacement plan, given distribution chain already built? And where are injectable capacity plans? (Ishit Desai)
• Answer: India's two largest pharma brands are also off the market; overall cough syrup consumption changed. Windlas approach: leverage multi-product liquid line, offer more liquid products, launch more pack-size variants, and expand across CDMO customers who dropped codeine. Injectable capacity addition decision would take 6-8 months (machinery, qualification); support infrastructure already in place; injectables "reasonably on track." (Hitesh Windlas)

API Price Impact & Volume vs. Price Growth

• Question: Has API price volatility impacted top line? Is CDMO growth volume-linked? (Vansh Gupta)
• Answer: API prices are volatile, not stabilized. Windlas is primarily cost-plus; historically maintained margins during falling API prices via customer partnership. Majority of this quarter's growth was volume-linked; API price impact is "unknown." Transparency approach: old stock offered at same old prices, price increases passed on by customers even on existing orders. (Hitesh Windlas, Komal Gupta)

Capacity Beyond ₹1,100 Crores & Export Catalysts

• Question: At ₹1,000 crores run-rate currently, when will further capacity addition be needed? What are export growth catalysts? (Resham Jain)
• Answer: ₹1,100 crores is "an easy go" with Plant 6, and debottlenecking through localised changes and small capex can push further. New capex decision will be taken when tracking shows capacity constraint; incremental (not mega) plant strategy preferred. Export focus: geographic expansion, portfolio expansion, plant approvals, registrations — all ongoing; conversions happen at particular quarters. (Ankit Jain, Hitesh Windlas)

Gross Margin Performance & Mix

• Question: What drove gross margin performance given lower trade generics mix (typically higher margin)? (Avnish Tiwari)
• Answer: Gross margins driven by business mix, operational efficiencies, and product portfolio within CDMO vertical converted this quarter. Lower trade generics/institutional revenue was a hit, offset by better products in CDMO. Management maintains margins at customer level, not quarterly; export growth also contributed. (Ankit Jain)

Key Takeaway

Windlas Biotech delivered its 14th consecutive record revenue quarter at ₹248 crores (18% YoY), with CDMO leading at ₹207 crores (29% YoY) while trade generics remained pressured at ₹30 crores post-codeine discontinuation and exports scaled 79% YoY to ₹11 crores. Profitability expanded — ex-ESOP EBITDA grew 26% to ₹34 crores and PAT 37% to ₹25 crores with EPS at ₹8.46 — supported by operational leverage and product mix in CDMO, despite 17% employee cost inflation from Uttarakhand minimum wage hikes and API price volatility from West Asia tensions. Management completed a ₹47 crores buyback and declared ₹6.30/share FY26 dividend while advancing Plant 6 commercialization for end-H1 FY27, which unlocks ₹1,100 crores+ revenue capacity and adds ~₹3 crores/quarter depreciation. Strategy remains disciplined incremental expansion rather than mega-facilities, maintaining CDMO pricing power, with trade generics recovery and export conversion pace as the key watch points for sustained earnings growth.